UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 321

Sortiert nach

Ceritinib Aggravates Glycemic Control in Insulin-treated Patients with Diabetes and Metastatic ALK-positive Lung Cancer

Internal Medicine, 2019, pp.1870-18

2019

Link zum Volltext

Verfügbarkeit prüfen

Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer

Oncotarget, 2018-04, Vol.9 (31), p.22137-22146

2018

Link zum Volltext

Verfügbarkeit prüfen

Design and synthesis of novel pyrimidine derivatives as potent antitubercular agents

European journal of medicinal chemistry, 2019-02, Vol.163, p.169-182

2019

Link zum Volltext

Verfügbarkeit prüfen

Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020)

Journal of hematology and oncology, 2020-10, Vol.13 (1), p.143-143, Article 143

2020

Link zum Volltext

Verfügbarkeit prüfen

Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention

Journal of clinical oncology, 2018-07, Vol.36 (21), p.2135-2144

2018

Link zum Volltext

Verfügbarkeit prüfen

A computational-based approach to fabricate Ceritinib co-amorphous system using a novel co-former Rutin for bioavailability enhancement

European journal of pharmaceutics and biopharmaceutics, 2023-09, Vol.190, p.220-230

2023

Link zum Volltext

Verfügbarkeit prüfen

The role of the ALK receptor in cancer biology

Annals of oncology, 2016-09, Vol.27 Suppl 3 (Suppl 3), p.iii4-iii15

2016

Link zum Volltext

Verfügbarkeit prüfen

Case Report: Patient With Lung Adenocarcinoma With ALK-HLA-DRB1 Rearrangement Shows Impressive Progression-Free Survival After Sequential Crizotinib and Ceritinib Treatment

Frontiers in oncology, 2022-02, Vol.12, p.762338

2022

Link zum Volltext

Verfügbarkeit prüfen

Opportunities and challenges in using real-world data for health care

The Journal of clinical investigation, 2020-02, Vol.130 (2), p.565-574

2020

Link zum Volltext

Verfügbarkeit prüfen

Treatment of advanced ALK-rearranged NSCLC following second-generation ALK–TKI failure

Expert review of anticancer therapy, 2023-11, Vol.23 (11), p.1157-1167

2023

Link zum Volltext

Verfügbarkeit prüfen

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2017-09, Vol.12 (9), p.1357-1367

2017

Link zum Volltext

Verfügbarkeit prüfen

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer

Pharmaceuticals (Basel, Switzerland), 2020-12, Vol.13 (12), p.474

2020

Link zum Volltext

Verfügbarkeit prüfen

Acute Interstitial Lung Disease Induced by Rechallenge with Ceritinib

Internal Medicine, 2020, pp.2597-18

2020

Link zum Volltext

Verfügbarkeit prüfen

Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies

Journal of Immunology Research, 2018-01, Vol.2018, p.6984948-17

2018

Link zum Volltext

Verfügbarkeit prüfen

Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non–Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study

Journal of thoracic oncology, 2020-03, Vol.15 (3), p.392-403

2020

Link zum Volltext

Verfügbarkeit prüfen

Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs

EBioMedicine, 2018-10, Vol.36, p.553-562

2018

Link zum Volltext

Verfügbarkeit prüfen

Ceritinib (LDK378) prevents bone loss via suppressing Akt and NF-κB-induced osteoclast formation

Frontiers in endocrinology (Lausanne), 2022-11, Vol.13, p.939959-939959

2022

Link zum Volltext

Verfügbarkeit prüfen

Case Report: Short-Term Response to First-Line Crizotinib Monotherapy in a Metastatic Lung Adenocarcinoma Patient Harboring a Novel TPR-ROS1 Fusion

Frontiers in oncology, 2022-04, Vol.12, p.862008

2022

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

BMC cancer, 2020-04, Vol.20 (1), p.328-328, Article 328

2020

Link zum Volltext

Verfügbarkeit prüfen

Could Drug Availability Be Improved through Shape Modification?

Chemical engineering & technology, 2023-11, Vol.46 (11), p.2292-2300

2023

Link zum Volltext

Verfügbarkeit prüfen

Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring PRRC2B-ALK Rearrangement: A Case Report

Frontiers in oncology, 2022-02, Vol.12, p.761558

2022

Link zum Volltext

Verfügbarkeit prüfen

Development and validation of UPLC–MS/MS method for the simultaneous quantification of anaplastic lymphoma kinase inhibitors, alectinib, ceritinib, and crizotinib in Wistar rat plasma with application to bromelain-induced pharmacokinetic interaction

Journal of pharmaceutical and biomedical analysis, 2021-09, Vol.204, p.114276-114276, Article 114276

2021

Link zum Volltext

Verfügbarkeit prüfen

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer

Cancers, 2015-04, Vol.7 (2), p.763-783

2015

Link zum Volltext

Verfügbarkeit prüfen

A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma

Neuro-oncology (Charlottesville, Va.), 2022-10, Vol.24 (10), p.1673-1686

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 321

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(274)
Mit Volltextzugriff
(293)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Ceritinib
(315)
Science & Technology
(253)
Life Sciences & Biomedicine
(239)
Crizotinib
(171)
Oncology
(165)
Humans
(142)
Alectinib
(135)
Lung Cancer
(121)
Non-Small Cell Lung Cancer
(100)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(95)
Lung Neoplasms - Drug Therapy
(93)
Anaplastic Lymphoma Kinase
(78)
Mutation
(67)
Protein Kinase Inhibitors - Therapeutic Use
(67)
Kinases
(60)
Brigatinib
(58)
Chemotherapy
(57)
Carcinoma, Non-Small-Cell Lung - Genetics
(55)
Lung Cancer, Non-Small Cell
(55)
Lymphoma
(55)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Ceritinib Aggravates Glycemic Control in Insulin-treated Patients with Diabetes and Metastatic ALK-positive Lung Cancer

Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)–Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study

Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer

Design and synthesis of novel pyrimidine derivatives as potent antitubercular agents

Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020)

Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention

A computational-based approach to fabricate Ceritinib co-amorphous system using a novel co-former Rutin for bioavailability enhancement

The role of the ALK receptor in cancer biology

Case Report: Patient With Lung Adenocarcinoma With ALK-HLA-DRB1 Rearrangement Shows Impressive Progression-Free Survival After Sequential Crizotinib and Ceritinib Treatment

Opportunities and challenges in using real-world data for health care

Treatment of advanced ALK-rearranged NSCLC following second-generation ALK–TKI failure

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer

Acute Interstitial Lung Disease Induced by Rechallenge with Ceritinib

Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies

Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non–Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study

Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs

Ceritinib (LDK378) prevents bone loss via suppressing Akt and NF-κB-induced osteoclast formation

Case Report: Short-Term Response to First-Line Crizotinib Monotherapy in a Metastatic Lung Adenocarcinoma Patient Harboring a Novel TPR-ROS1 Fusion

Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Could Drug Availability Be Improved through Shape Modification?

Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring PRRC2B-ALK Rearrangement: A Case Report

Development and validation of UPLC–MS/MS method for the simultaneous quantification of anaplastic lymphoma kinase inhibitors, alectinib, ceritinib, and crizotinib in Wistar rat plasma with application to bromelain-induced pharmacokinetic interaction

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer

A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma

Suchergebnisse filtern